. Introduction {#s02}
==============

Colorectal cancer (CRC) is one of the most common forms of cancer, accounting for approximately 1 in 10 new cancer diagnoses worldwide in 2012^[@b1]^. Radiotherapy is commonly used to treat rectal cancers prior to surgery or to treat inoperable colorectal metastases, in the form of stereotactic body radiotherapy or selective internal radiotherapy^[@b2]-[@b4]^.

International standard combination therapy for rectal cancer, radiotherapy delivered with 5-fluorouracil (5FU) as a radiosensitiser, is given either as an infusion or as an oral prodrug (capecitabine). There is currently no molecular basis for the selection of patients for radiotherapy, nor for the selection of any alternative drug to use as a radiosensitiser. With the current standard, sufficient downsizing by chemoradiotherapy is obtained by approximately half of patients treated^[@b5]^. There is scope for improving the radiotherapy approaches currently offered to patients. Clinical trials have added additional drugs to 5FU as a combination radiosensitising approach^[@b6],[@b7]^ without molecular selection, but these trials have not changed the international standard.

Colorectal tumours have a heterogeneous molecular background^[@b8]^. Commonly occurring CRC mutations that may be prognostic or can affect treatment decisions include *KRAS*, *BRAF* and *PIK3CA* mutations, which are found in 42%, 9% and 13% of CRC patients respectively^[@b9]^. KRAS, BRAF and PIK3CA are vital components of two main cellular signalling pathways; RAS/MEK/ERK and PI3K/AKT/mTOR; strongly inter-connected pathways that play central roles in tumorigenesis by regulating cell survival, proliferation, metabolism, and motility. The *KRAS* gene is a member of the oncogenic *RAS* gene family and binds to effector kinases including BRAF and phosphatidylinositol 3-kinase (PI3K). The *PIK3CA* gene encodes the PI3K p110α subunit, which interacts with RAS proteins^[@b10]^.

The commonest *BRAF* mutation in colorectal cancer, the V600E substitution, results in elevated kinase activity and constitutive downstream MEK and ERK phosphorylation^[@b11],[@b12]^. The presence of *BRAF* V600E in advanced CRC correlates with poor prognosis with markedly worse progression after chemotherapy^[@b13]-[@b15]^. *BRAF* mutation is predictive of poor response to cetuximab in metastatic CRC, also observed for *KRAS* and *PIK3CA* mutations^[@b16]-[@b18]^. Although patients with *BRAF*-mutant cancers do less well with chemotherapy, anti-EGFR therapies and surgery^[@b19]^, there is currently no suggestion that they benefit less from radiotherapy. Although *BRAF* mutation is relatively rare in rectal cancer, radiotherapy can also be used to treat inoperable liver metastases from CRC. It has been suggested that CRC liver metastases respond less well to radiotherapy than liver metastases from other primary malignancies^[@b20]^, hence the addition of a radiosensitising drug may be of value to improve the therapeutic index during radiotherapy^[@b21]^.

Our aim was to develop a radiosensitiser drug discovery assay enabling identification of drugs that will enhance radiotherapy more effectively than the current standard, 5FU, and demonstrate activity in defined molecular backgrounds. Firstly, we developed a high throughput screen (HTS), in CRC cell lines, to identify drugs that could be effective radiosensitisers in the context of *BRAF* V600E activating mutations. The drugs identified during the screen were validated across an extensive panel of human CRC cell lines, selected to represent aspects of the molecular landscape of CRC; including *BRAF* V600E in both MSI and MSS backgrounds, and a spectrum of *KRAS*, *PIK3CA* and *p53* mutations. Such cell line panels recapitulate the different subtypes found in CRC, are representative of genetic alterations found in primary cancers and are good predictors of clinical efficacy during drug development programmes^[@b22]^. Here, we use this model to test new drug-radiotherapy combinations for the first time, identifying PARP inhibitors as the most strongly radiosensitising class of agent before validating by clonogenic survival assays and *in vivo* xenograft studies.

. Materials and methods {#s03}
=======================

. Cell lines, drug library and irradiations {#s03.01}
-------------------------------------------

The parental CRC cell lines RKO (*BRAF V600E/V600E/WT*) and VACO432 (*V600E/WT*) and their isogenic pairs RKO-T29 (*BRAF WT/-/-*) and VACO432-VT1 (BRAF WT/-) were a gift from Sandra Van Schaeybroeck, Queens University, Belfast, UK (mutation status confirmed by sequencing). The panel of colorectal cancer cell lines utilised for cell proliferation assays was obtained from Prof. Walter Bodmer, University of Oxford, UK. The cell line panel is listed in **[Supplementary Table S1](#TableS1){ref-type="table"}**, and has been previously described^[@b22]^. Non-malignant cell lines were obtained from Prof. Gillies McKenna, University of Oxford, UK. All cell lines were used within 12 passages, or where necessary, replenished using frozen aliquots of the initial passage. Isogenic cell lines were grown in McCoy\'s 5A (Modified) Medium, and other cell lines in DMEM; both supplemented with 10% Fetal Bovine Serum and 1 × penicillin/streptomycin (Thermofisher Scientific Inc., MA, USA), in a 37°C, 5% CO~2~, humidified incubator. The small compound anti-cancer drug library was provided in 384-well plate format (Target Discovery Institute, University of Oxford), and contained 222 drugs from the TDI Extended Oncology Drugs Library (ODL) and 76 from the NCI Developmental Therapeutics Program (DTP) Approved Oncology Drug set (**[Supplementary Table S2](#TableS2){ref-type="table"}**).

A GSR D1 irradiator (Gamma-Service Medical GmbH, Leipzig, Germany) a Cs-137 source, (dose rate 1.5 Gy/min) was used for cell irradiations. For xenografts, a RS320 X-ray irradiator (Gulmay Limited, Byfleet, UK) was used (1.6 Gy/min), with lead shielding to localise dose to tumor. Dosimetry was calculated from optical density of scanned Gafchromic EBT3 film (Ashland, NJ, USA), corrected and calibrated to the National Physical Laboratory (Teddington, UK) primary standard.

. High-throughput drug screen with ionising radiation {#s03.02}
-----------------------------------------------------

Methodology and data analysis followed internationally recognised high-throughput screening guidelines^[@b23]^. *BRAF V600E* isogenic RKO and VACO432 cells were seeded in 52 μL/well by Flexdrop (PerkinElmer, MA, USA). Seeding density in 384-well plates was 300 cells/well (RKO) and 1,000 cells/well (VACO432). Eighteen hours after seeding, cells were screened with 298 oncological drugs, in 5-fold dilutions from 10 μM--16 nM. Janus workstations (PerkinElmer, MA, USA) were used to transfer 13 μL of compound from library plate to cell culture plates. Positive controls were PI103 and vorinostat, negative controls were vehicle (DMSO) alone. After 6 h, plates were either mock-irradiated, or irradiated with 4 Gy. Media was replaced 24 h following treatment, and surviving cells allowed to proliferate for five doubling times as optimised in preliminary screens. Cell viability was measured by resazurin (10 μg/mL) in phenol red-free DMEM. Metabolically viable cells reduce resazurin to fluorescent resorufin, which was quantified by PerkinElmer Envision microplate reader (540 nm excitation/590 nm emission). Control wells reached 90%--100% confluency at the time of assay performance, control irradiated wells were around 60% confluent. Raw data were normalized by rescaling to plate mean intensity and to negative controls. Quality plots were contrasted to assess artifacts and reproducibility. Normalized data Z are presented, as the applied rescaling by plate mean is effectively a z-score standardization. Selection of candidate hits was based on rank product analysis, adapting a published method^[@b24]^. Specifically, for each pair of conditions (i.e. with/without irradiation), the differences between normalised screen intensities were calculated for each well, hence each drug. These differences are presented as Delta-Z (ΔZ) scores. Rank product applied to these differences identified compounds producing large and consistent changes. Probability of false discovery was computed by permutation, with *n* = 100. Analyses were implemented in R version 2.1 (https://cran.r-project.org/); heatmaps were generated by modifying D3.js libraries (https://d3js.org/).

. Cell proliferation and colony formation assays {#s03.03}
------------------------------------------------

Our method for comparison of IC~50~ in the presence or absence of radiation has been described previously^[@b25]^. Clonogenic survival was measured following a standard method, with plating efficiency and surviving fractions calculated as described^[@b26]^. Briefly, cells were seeded into 10 cm culture dishes, normally 500 cells/plate (for 0 Gy plates), increasing by 10-fold for each 4 Gy administered, to 500,000 cells/plate (12 Gy). After attachment (overnight), cells were drug-treated, and six hours later exposed to 0, 4, 8 or 12 Gy radiation. Culture medium was replaced 24 hours post-irradiation, plates were incubated to form visible colonies \> 50 cells (10 -- 15 days) and fixed with 0.4% methylene blue in methanol. Survival curves were fitted using Graphpad Prism v7.0A. Radiation enhancement ratio (RER) was obtained from the ratio of radiation dose at 1% survival of vehicle compared with drug treated cells.

. Xenograft studies {#s03.04}
-------------------

Animal experiments were performed following local ethical review under licence from the UK Home Office (ASPA 1986, revised January 2013). Female Balb/c nude mice (6--8 weeks old) were anaesthetised with 2% isoflurane and subcutaneously injected with 50% matrigel containing 5x10^6^ DLD1 cells or 5 × 10^6^ RKO/mouse (*n* = 24) into the back. When tumor volume reached 100 mm^3^, mice were randomly placed into 4 groups (*n* = 6/group). Oral treatments were by gavage, in two doses on the first and fourth days of treatment. Group (1) received vehicle only, 10% dimethylacetamide/6% solutol HS/PBS (0.1mL/10 g body weight). Group (2) received talazoparib; 0.1 mg/kg in vehicle. Radiation treatments comprised 2 × 5 Gy, localised to the tumor, also on the first and fourth days of treatment. Group (3) received radiation only, 5 Gy one hour after each vehicle treatment. Group (4) received combination treatment, 5 Gy one hour after each talazoparib treatment. Tumor size was measured by caliper 3 × per week. Mice were sacrificed when tumours reached 400 mm^3^ or 42 days following the first treatment. Tumours were formalin fixed and stained for the hypoxia marker CA9 as previously described^[@b27]^.

. Results {#s04}
=========

. Development of a high throughput screen with ionising radiation {#s04.01}
-----------------------------------------------------------------

In order to identify drugs that radiosensitise CRC cells mutated for BRAF V600E, isogenic cell lines containing either BRAF V600E or BRAF WT variants were screened against a 298-compound library of approved anticancer drugs. Mutation status for KRAS, PIK3CA and p53 for these cell lines is shown in **[Figure 1A](#Figure1){ref-type="fig"}**, with the screen protocol outlined in **[Figure 1B](#Figure1){ref-type="fig"}**.

![High-throughput screening of FDA approved cancer drugs to identify which drugs should be used for radiosensitisation in the context of single gene mutations in colorectal cancer.](cbm-16-2-234-1){#Figure1}

A prerequisite for high-throughput detection of radiosensitisers is an assay that is predictive of the effects of drug/ radiation combinations on clonogenic cell survival. Extended incubation following irradiation improves correlation with radiosensitisation^[@b28]^, and we incorporated 5 days incubation following radiation treatment; improving correlation to clonogenic survival, but avoiding compromises to cell metabolism and thus assay performance^[@b29]^. Serial dilution of cells in the presence of resazurin showed equivalent fluorescence, linear in relation to cell number, for both non-irradiated cells, and cells 5 days post-irradiation (data not shown). This indicates that the metabolic assay was a good surrogate for cell number at this timepoint.

Screens were carried out in duplicate and quality plots demonstrated good reproducibility (**[Figure 1C](#Figure1){ref-type="fig"}**), with mean Pearson correlation between pairs of replicates of 0.88 and average Z factor of 0.58 for irradiated and 0.53 for non-irradiated plates. Cell viability was compared between normalized irradiated and non-irradiated plates, generating heatmaps of the difference, ΔZ, for each compound. Hit selection (**[Figure 1D](#Figure1){ref-type="fig"}**) was based on rank product analysis, with the probability of false discovery computed by permutations (see Materials and methods). Potential hits were drugs that sensitised the BRAF-mutant isogenic variant, at one or more concentrations, with probability of false positive (PFP) ≤ 0.05. Some plates showed a pronounced 'edge effect', and for this reason, analysis was repeated considering the edge wells as a separate population (**[Figure 1E](#Figure1){ref-type="fig"}**). Hits with significant ΔZ score between irradiated and non-irradiated samples, with radiosensitisation factor \< 1 (normalised against control plates) and *P*-value ≤ 0.05 were selected as significant. Positive controls were consistently identified as hits, with ΔZ scores ≤ 2, comparable to results obtained in manual assays.

 {#s04.02}

BRAF V600E screen in isogenic cell lines following irradiation

Drugs were ranked according to radiosensitisation against *BRAF*-mutated cells. The fifteen drugs with the highest significance against *BRAF*-mutated cells are shown in **[Table 1](#Table1){ref-type="table"}**. Seven hits have previously been identified as radiosensitisers in the published literature^[@b30]-[@b36]^, helping to validate our methodology. Five hits were inhibitors of RAS/RAF/MEK/ERK pathway (trametinib, TAK-733, pimasertib, doramapoimod and dactolisib), predominantly acting in *BRAF* WT and V600E. Eight drugs reached significance in the *BRAF*-mutant cell line but not in *BRAF* WT, including the CHK1 inhibitor, PF477736. Another CHK1 inhibitor, AZD7762, radiosensitised both *BRAF* variants.

###### 

Fifteen radiosensitisers identified for *BRAF*-mutant cells

  -----------------------------------------------------------------------------------------------
  Compound       Effective concentration\   Effective concentration\   Mechanism of action
                 in RKO (BRAF mut) (μM)     in RKO (BRAF WT) (μM)      
  -------------- -------------------------- -------------------------- --------------------------
  Dactolisib     0.016, 0.4                 0.016                      Dual PI3K/mTOR inhibitor

  Panobinastat   0.016                      ns                         HDAC inhibitor

  Trametinib     0.016                      0.016                      MEK inhibitor

  ABT-199        0.08                       0.08                       Bcl-2 inhibitor

  Olaparib       0.08                       ns                         PARP inhibitor

  Tosedostat     0.08                       ns                         Peptidase inhibitor

  AZD 7762       0.08                       0.08                       Chk inhibitor

  Pimasertib     0.4, 0.08                  0.08                       MEK inhibitor

  PF477736       0.08                       ns                         Chk1 inhibitor

  17-AAG         0.08                       ns                         Hsp90 inhibitor

  Doramapimod    0.08                       ns                         p38 MAPK inhibitor

  Danusertib     0.08                       ns                         aurora kinase inhibitor

  Serdametan     0.4                        0.4                        MDM2 inhibitor

  Tak-733        0.4                        0.4                        MEK inhibitor

  Auranofin      0.4                        ns                         Gold complex
  -----------------------------------------------------------------------------------------------

The poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib, significantly increased sensitivity to irradiation in *BRAF* V600E RKO cells. In a separate screen of *BRAF* isogenic Vaco432 cells, olaparib also radiosensitised *BRAF* V600E Vaco432 cells at 16 nM and 80 nM (*P* ≤ 0.05, data not shown). Based on these data, radiosensitisation by PARP inhibitors (PARPi) in RKO isogenic for V600E and WT, was validated by long-term proliferation assay at a broad concentration range and by clonogenic cell survival assay (**[Figure 2](#Figure2){ref-type="fig"}**). Olaparib as a single agent had little effect on survival, but combination treatment caused a significant increase in radiation sensitivity, albeit with similar effect in both *BRAF* WT and V600E variants.

![Validation of radiosensitisation effects of olaparib in BRAF-mutant and BRAF-WT isogenic CRC cells.](cbm-16-2-234-2){#Figure2}

. Radiosensitisation in an extended CRC cell line panel {#s04.03}
-------------------------------------------------------

To validate the screen, we used a cell line panel inclusive of the different molecular subtypes of CRC. We specifically prioritised the drug hits with the most immediate scope for translation to clinical trials in combination with radiotherapy. The cell line panel was selected so that several cell lines exhibited each gene mutation of interest. Fifteen cell lines with defined *BRAF*, *p53*, *KRAS*, *PIK3CA* and mismatch repair status were used. The compounds chosen for further testing are shown in **[Table 2](#Table2){ref-type="table"}**, along with *p*-values indicating whether significant IC~50~ shift was observed following normalisation for radiation effect. The complete IC~50~ results determined by these assays are shown in **[Supplementary Table S3](#TableS3){ref-type="table"}**.

###### 

*P*- values for radiosensitisation by 11 drugs across a panel of 15 CRC cell lines

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cell line      LS411                  Vaco5                                                                                                  RKO          HT29         OXCO4       CCK81         HCA7      DLD1        CW2             C10          HT55      C99       Colo678     SW403       SW1222       
  -------------- ---------------------- ------------------------------------------------------------------------------------------------------ ------------ ------------ ----------- ------------- --------- ----------- --------------- ------------ --------- --------- ----------- ----------- ------------ ---------
  BRAF           BRAF V600E             BRAF V600E                                                                                             BRAF V600E   BRAF V600E   BRAFV600E   BRAFWT        BRAFWT    BRAFWT      BRAFWT          BRAFWT       BRAFWT    BRAFWT    BRAFWT      BRAFWT      BRAFWT       

  MSI status     MSI                    MSI                                                                                                    MSI          MSS          MSS         MSI           MSI       MSI         MSI             MSS          MSS       MSS       MSS         MSS         MSS          

  KRAS           KRAS WT                KRAS WT                                                                                                KRAS WT      KRAS WT      KRAS WT     KRAS WT       KRAS WT   KRAS G13D   KRAS P140H      KRAS WT      KRAS WT   KRAS WT   KRAS G12D   KRAS G12V   KRAS A146V   

  EGFR           EGFR MUT               EGFR WT                                                                                                EGFR WT      EGFR WT      Not known   EGFR Y1069C   EGFR WT   EGFR WT     EGFR G544\*FS   EGFR WT      EGFR WT   EGFR WT   EGFR WT     EGFR WT     EGFR WT      

  Compound       Target                 Radiosensitisation response (+ indicates significant radiosensitisation, with *P* value given below)                                                                                                                                                                   

  5-fluoro-\     Thymidylate synthase   ns                                                                                                     ns           ns           ns          ns            ns        ns          ns              \+*p*≤0.01   ns        ns        ns          ns          ns           ns
  uracil                                                                                                                                                                                                                                                                                                       

  SAHA           HDAC                   ns                                                                                                     ns           +≤ 0.05      ns          +≤ 0.01       ns        ns          ns              ns           ns        +≤ 0.01   +≤ 0.05     +≤ 0.01     +≤ 0.01      +≤ 0.05

  PI-103         PI3K/\                 +≤ 0.05                                                                                                ns           +≤ 0.01      ns          +≤ 0.01       +≤ 0.05   +≤ 0.01     +≤ 0.01         +≤ 0.01      ns        ns        +≤ 0.01     +≤ 0.01     +≤ 0.05      +≤ 0.01
                 DNAPK/\                                                                                                                                                                                                                                                                                       
                 mTOR                                                                                                                                                                                                                                                                                          

  Olaparib       PARP                   +≤ 0.01                                                                                                +≤ 0.01      +≤ 0.01      +≤ 0.01     +≤ 0.01       +≤ 0.01   +≤ 0.01     +≤ 0.01         ns           ns        +≤ 0.01   +≤ 0.01     ns          +≤ 0.01      +≤ 0.01

  Rucaparib      PARP                   +≤ 0.01                                                                                                +≤ 0.01      +≤ 0.01      +≤ 0.01     +≤ 0.05       +≤ 0.01   +≤ 0.01     +≤ 0.01         ns           ns        +≤ 0.05   +≤ 0.05     ns          +≤ 0.01      +≤ 0.01

  AZD-7762       CHK1 and 2             ns                                                                                                     ns           +≤ 0.05      ns          +≤ 0.01       +≤ 0.01   +≤ 0.05     +≤ 0.05         +≤ 0.01      +≤ 0.01   ns        +≤ 0.01     +≤ 0.01     +≤ 0.05      ns

  PF477736       CHK1 and 2             +≤ 0.05                                                                                                +≤ 0.05      +≤ 0.05      +≤ 0.05     +≤ 0.05       +≤ 0.01   +≤ 0.01     +≤ 0.01         +≤ 0.01      +≤ 0.01   +≤ 0.05   ns          ns          +≤ 0.01      +≤ 0.05

  AZD-6244       MEK1 and 2             ns                                                                                                     +≤ 0.05      +≤ 0.01      ns          +≤ 0.01       ns        +≤ 0.01     ns              +≤ 0.01      +≤ 0.05   +≤ 0.05   ns          +≤ 0.01     +≤ 0.01      +≤ 0.01

  Trametinib     MEK1 and 2             +≤ 0.05                                                                                                ns           +≤ 0.01      ns          ns            +≤ 0.05   +≤ 0.01     +≤ 0.01         ns           +≤ 0.05   ns        +≤ 0.05     +≤ 0.01     ns           +≤ 0.01

  Mitoxantrone   TOPO II                ns                                                                                                     ns           ns           +≤ 0.05     ns            +≤ 0.05   +≤ 0.05     +≤ 0.01         +≤ 0.01      ns        +≤ 0.05   ns          ns          +≤ 0.01      ns

  Vemurafenib    BRAF V600E             ns                                                                                                     ns           ns           ns          ns            ns        ns          ns              ns           ns        ns        ns          ns          ns           ns
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

From these assays, olaparib and rucaparib displayed potent radiosensitising ability across multiple cell lines. IC~50~ curves (normalised for radiation effect) were significantly different (*P* ≤ 0.01) for all except three cell lines; namely, C10, CW2 and Colo678 (**[Table 2](#Table2){ref-type="table"}**).

Both Chk1 inhibitors, and trametinib, were also effective radiosensitisers in the majority of cell lines tested. Vemurafenib was ineffective in *BRAF* WT (IC~50~ frequently not reached), but showed some efficacy in *BRAF* mutated cell lines, (not significant for radiosensitisation). This limited effect may arise from feedback activation of EGFR, PI3K or alternative signaling pathways, reducing vemurafenib efficacy in CRC when compared to melanoma^[@b37]^.

. Validation of radiosensitisation by PARP inhibitors with clonogenic survival assays {#s04.04}
-------------------------------------------------------------------------------------

As PARPi were the most effective radiosensitisers of the CRC cell line panel, clonogenic survival assays were used to measure radiation enhancement ratios (RERs) in 3 cell lines that were strongly radiosensitised (\> 10-fold IC~50~ shift) and 3 cell lines with IC~50~ shift \< 10-fold. To potentially improve PARPi radiosensitisation of these resistant cell lines, a more trapping PARPi, talazoparib, was included in these assays. Survival curves ( **[Figure 3](#Figure3){ref-type="fig"}**), and RERs (**[Table 3](#Table3){ref-type="table"}**) reflected the proliferation assay results: Olaparib and rucaparib significantly radiosensitised RKO, DLD1, and HT29 compared to vehicle-treated cells, while radiosensitisation of HT55, Colo678, and C10 was limited -- although significant for HT55 cells treated with rucaparib. Talazoparib significantly radiosensitised all cell lines tested, and was overall the most effective radiosensitiser (average RERs 1.21--1.92), followed by rucaparib (average RERs 1.15--1.41) and finally olaparib (average RERs 1.12--1.4).

![Clonogenic assays to confirm radiosensitisation of multiple cell lines by PARP inhibitors.](cbm-16-2-234-3){#Figure3}

###### 

Radiation enhancement ratios of PARP inhibitors for colorectal cancer and non-malignant cell lines

  Gene mutation status                 Radiation enhancement ratio (*P*-value)                                                                          
  -------------------------- --------- ----------------------------------------- ---------- ------- -- ----------------------- ------------------------ ------------------------
  CRC cell lines                                                                                                                                        
  RKO                        p.V600E   WT                                        p.H1047R   WT         **1.48 (*P* ≤ 0.05)**   **1.41 (*P* ≤ 0.05)**    **1.71 (*P* ≤ 0.001)**
  HT29                       p.V600E   WT                                        WT         R273H      **1.44 (*P* ≤ 0.01)**   **1.28 (*P* ≤ 0.001)**   **1.82 (*P* ≤ 0.001)**
  DLD1                       WT        G13D                                      p.E545K    S241F      **1.18 (*P* ≤ 0.01)**   **1.21 (*P* ≤ 0.01)**    **1.92 (*P* ≤ 0.001)**
  HT55                       WT        WT                                        WT         R213L      1.21 (ns)               **1.31 (*P* ≤ 0.01)**    **1.39 (*P* ≤ 0.01)**
  C10                        WT        WT                                        WT         G245S      1.12 (ns)               1.18 (ns)                **1.48 (*P* ≤ 0.001)**
  Colo678                    WT        G12D                                      WT         WT         1.12 (ns)               1.15 (ns)                **1.21 (*P* ≤ 0.001)**
  Non-malignant cell lines                                                                                                                              
  HFLA                       n/a       n/a                                       n/a        n/a        1.09 (ns)               **1.3 (*P* ≤ 0.05)**     1.29 (ns)
  MRC5                       n/a       n/a                                       n/a        n/a        **1.35 (*P* ≤ 0.05)**   **1.34 (*P* ≤ 0.05)**    **1.52 (*P* ≤ 0.01)**
  RPE                        n/a       n/a                                       n/a        n/a        1.1 (ns)                1.07 (ns)                **1.24 (*P* ≤ 0.01)**

To indicate potential normal tissue toxicity, PARPi experiments were repeated in three non-malignant cell lines, HFLA, MRC5 and RPE. In clonogenic assays (**[Table 3](#Table3){ref-type="table"}**), these non-malignant cells were significantly radiosensitised by talazoparib. Radiosensitisation by rucaparib was significant for HFLA and MRC5, and radiosensitisation by olaparib was significant only for MRC5 cells (*P* ≤ 0.05).

. Validation of PARP inhibitors as radiosensitisers in xenograft studies {#s04.05}
------------------------------------------------------------------------

The PARP inhibitor talazoparib was the most effective radiosensitiser and had not previously been tested with radiotherapy in animal CRC models. To confirm the *in vitro* radiosensitisation by PARPi in an *in vivo* model, talazoparib was tested against two cell lines that were effectively radiosensitised by the drug in 2D assays. Mice were inoculated with subcutaneous tumors consisting of RKO or DLD1 cells, and treated with talazoparib or vehicle, either alone or one hour before each of 2 × 5 Gy radiation treatments. In DLD1 cells (**[Figure 4A](#Figure4){ref-type="fig"}**), single treatment with talazoparib or radiation alone did not inhibit tumour growth. Combined talazoparib/radiation treatment was tolerated by the mice, and significantly reduced tumour growth compared with radiation alone (*P* ≤ 0.01). For the RKO cell xenograft model, there was no significant difference between the effect of radiation alone, and the radiation/talazoparib combination. Tumour histology, levels of perinecrotic hypoxia (CA9 staining) and necrosis were similar for both cell types (**[Figure 4B](#Figure4){ref-type="fig"}**).

![Talazoparib significantly enhances the response of colorectal cancer cells grown *in vivo* to ionizing radiation.](cbm-16-2-234-4){#Figure4}

. Discussion {#s05}
============

The aim of this study was to identify treatment options to radiosensitise colorectal cancer cells in the context of key mutations that characterise the disease. Biopsies from CRC patients are routinely screened for *BRAF*, *KRAS* and *PIK3CA* mutations, but this information is not currently used in treatment decisions regarding radiotherapy. There is preclinical evidence that single gene alterations in cancer can determine the extent of radiosensitisation exerted by different drugs. Examples include mammalian AMP-activated protein kinase dependence of pancreatic cancer cells to radiosensitisation by metformin^[@b38]^, the role of mismatch repair deficiency in radiosensitisation of CRC cell lines by gemcitabine^[@b39]-[@b40]^ and p53-dependent radiosensitisation by valproic acid^[@b41]^. Radiosensitisation drug discovery across different genetic backgrounds may enable a change from a "one size fits all" chemo- radiotherapy to the identification of the most appropriate drugs for radiotherapy based on the genetic profile of the cancer.

To address our primary aim, we developed a novel high-throughput screen to test drug library/radiotherapy combination against cell lines. For drug repurposing, which allows more rapid translation in to the clinic, we used a library of drugs already in clinical use or in clinical trials. Previous investigators using more focused library screens have successfully identified radiosensitisers of CRC^[@b42]^ and our study identified the same drugs with radiosensitising potential, the CHK inhibitor, AZD-7762, and the dual mTOR/PI3K inhibitor, dactosilib. We initially used isogenic cell lines to identify radiosensitisers active in a *BRAF* V600E background. Reassuringly, our results confirmed radiosensitisation by agents from drug classes previously shown to have radiosensitising activity in other published papers, such as inhibitors of the RAS/MEK/ERK, and PI3K/MTOR pathways. In addition, we identified compounds not previously known to be radiosensitisers (**[Table 1](#Table1){ref-type="table"}**). Of the drugs targeting mutated BRAF (vemurafenib, dabrafenib, RAF265), only vemurafenib reached the threshold for hit-detection in the screen, possibly because vemurafenib is a more potent radiosensitizer, at least compared with dabrafenib^[@b43]^.

Cell lines manipulated by gene mutation might not be entirely representative of the molecular landscape of cancer in patients. We therefore validated results from isogenic cell lines in a panel of human colorectal cancer cell lines, inclusive of common CRC mutations and previously shown to be a useful model for drug development^[@b22],[@b44]^. This approach was also novel since this cell line panel has not previously been used to test new drug-radiotherapy combinations. The results (shown in **[Table 2](#Table2){ref-type="table"}**), confirmed PARPi as significant radiosensitisers, notably across a much broader range of cell lines than 5FU, the current clinical standard, suggesting that 5FU may not be the optimal treatment for all CRC patients compared to newer and more targeted drugs. This reflects data in other studies in CRC, which show that radiosensitisation by 5FU varies depending on the cell line used^[@b45],[@b46]^. Additionally, the timing of 5FU exposure may influence the degree of radiosensitisation^[@b47]^.

In future, immunotherapy is likely to be of increasing importance in CRC treatment, although at present it is only used to treat the more immunogenic MSI-high tumours^[@b48]^. Despite this, radiotherapy is likely to remain an important treatment for rectal cancer and metastatic disease, particularly when the cost effectiveness of treatment is considered. The broad range of cell lines for which PARPi appear to be suitable radiosensitisers in this study may predict its potential future utility in a wide patient population.

Three PARPi, olaparib, rucaparib, and niraparib, have been approved by the US FDA for the treatment of ovarian cancer, including BRCA-deficient tumours that have deficient homologous recombination repair. PARPi function by inhibiting the binding, or enzymatic activity, of PARP to single strand breaks in DNA. The absence of SSB repair leads to double strand break (DSB) formation at the approaching replication fork, and cell death. It has been shown that PARPi have an increased radiosensitising effect on DSB- repair deficient tumour cells compared with DSB- repair proficient lines^[@b49]^. Compared to olaparib and rucaparib, we found that talazoparib treatment led to higher RERs. PARPi affect cell proliferation by two main actions: inhibiting PARP enzymatic function, and by binding ('trapping') PARP to DNA^[@b50]^. Olaparib and rucaparib function primarily through inhibiting enzymatic function, whereas talazoparib 'traps' PARP at DNA damage sites, with increased anti-proliferative effect, potentially contributing to more effective radiosensitisation^[@b51],[@b52]^.

We proceeded to show that the PARP inhibitor, talazoparib, radiosensitised DLD1 xenografts *in vivo*. The combined treatment caused a prolonged tumour growth delay, in excess of the effects demonstrated elsewhere for combined 5FU/radiation treatment for HCT116^[@b45]^ and WiDr^[@b53]^ CRC xenografts. It is unclear why talazoparib did not significantly radiosensitise *BRAF* mutated RKO xenografts *in vivo*. It has been shown that *BRAF*-mutant early neoplastic lesions have upregulation of gene sets involved in aberrant DNA methylation^[@b54]^ and that *BRAF*-mutant cancers can have distinct tumour-associated-stroma and components of the extracellular matrix that are different from wild-type cancers^[@b55]^. These complexities may explain the discrepancy between the highly significant results we obtained in 2D culture and the non-significant results we obtained *in vivo* using the same cell line. Future studies should consider the use of other models, such as patient-derived xenografts or immunocompetent mouse models, to explore this discrepancy further.

Some investigators advocate preclinical comparison of non-malignant with malignant cell lines to identify cancer-specific drugs^[@b56],[@b57]^. In our study, olaparib did not cause significant radiosensitisation of two non-malignant cell lines, HLA and RPE. An *in vivo* study of intestinal crypt damage, in which fractionated radiotherapy was combined with olaparib, did not appear to cause additional gut toxicity compared to radiotherapy without drug^[@b58]^. Contrastingly, clinical studies of PARPi have documented bowel toxicities as side effects of treatment^[@b59]^ and total body irradiation of a p21-reporter mouse has shown that olaparib can exacerbate DNA damage in normal tissues when combined with radiation^[@b60]^. It should be noted that, in our study, rucaparib and talazoparib caused significant radiosensitisation of 2 non-malignant cells tested by clonogenic survival assays. Although talazoparib has already completed phase I development as a single agent^[@b61]^, we recommend that the normal tissue toxicity from the combination of PARPi with radiotherapy should be assessed further in preclinical normal tissue toxicity models and monitored closely in early-phase clinical trials.

In conclusion, our novel approach to radiosensitisation drug discovery in cells isogenic for the *BRAF V600E* mutation, has led to the identification of PARPi as radiosensitisers for CRC. Validation in a broad panel of human CRC cell lines, and an *in vivo* xenograft model, has shown potentially broader radiosensitising activity than the current clinical standard of care, 5FU. Following toxicity evaluation of the combination of PARPi with radiotherapy in other preclinical models, we propose that PARP inhibition should be tested in combination with radiotherapy for rectal cancer or metastatic CRC treatment, with careful monitoring of potential toxicities.
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###### 

Details of the cell lines

  Cell line   *BRAF*   *KRAS*   *PIK3CA*       *P53*        MSI/MSS   CIMP
  ----------- -------- -------- -------------- ------------ --------- -------
  C10         WT       WT       WT             WT           MSS       CIMP-
  C99         WT       WT       WT             WT           MSS       CIMP-
  CCK81       WT       WT       C420R, C472Y   P278H        MSI       CIMP-
  COLO678     WT       G12D     WT             WT           MSS       CIMP+
  CW2 †       WT       P140H    P283S          WT           MSI       na.
  DLD1        WT       G13D     E545K          S241F        MSI       CIMP+
  HCA7        WT       WT       WT             P301fs\*44   MSI       CIMP+
  HT29        V600E    WT       WT             R273H        MSS       CIMP+
  HT55        V600E    WT       WT             .R213L       MSS       CIMP-
  LS411       V600E    WT       WT             Y126\*       MSI       CIMP+
  OXCO4 †     V600E    WT       WT             mutant       MSS       na.
  RKO         V600E    WT       H1047R         WT           MSI       CIMP+
  SW1222      WT       A146V    WT             WT           MSS       CIMP-
  SW403       WT       G12V     Q546K          E51\*        MSS       CIMP-
  VACO5 †     WT       WT       H1047R         mutant       MSI       na.

###### 

Anticancer drugs comprising the small compound library for the screen

  ------------------------------------- ----------------------------------------- --------------------------------------- ---------------------------------- -------------------------------
  (5Z)-7-Oxozeaenol                     Bleomycin                                 FK 506_Tacrolimus                       Mitomycin C                        Rapamycin (sirolimus)

  (R)-Flurbiprofen (Tarenflurbil)       BMS-754807                                FK-866 HCl_Daporinad                    Mitotane                           RD162

  1-methyl-D-tryptophan, 95%            BMS-911543                                Floxuridine                             Mitoxantrone                       RDEA119_Refametinib

  17-AAG (Tanespimycin, Geldanamycin)   Bortezomib                                Fludarabine                             MK-0752                            Ridaforolimus

  17-DMAG (Alvespimycin)                Bosutinib                                 Fluorouracil                            MK-2206                            Rofecoxib (Vioxx)

  2-methoxyestradiol (Panzem)           Brivanib                                  Flutamide                               MK-4827, HCl salt                  Romidepsin

  4-hydroxytamoxifen                    Busulfan                                  Fulvestrant                             MK1775                             Roscovitine_Selicilib

  Abitrexate/Methotrexate               Cabazitaxel                               Galiellalactone                         MLN4924                            S-trityl-L-cysteine, 40 mM

  ABT-199                               CAL-101                                   GDC-0068                                MLN8237_Alisertib                  SB 743921

  ABT-263 (Navitoclax)                  Camptothecin                              GDC-0941_Pictilisib                     Motesanib Di phosphate (AMG-706)   Simvastatin

  ABT-751                               Canertinib                                GDC-0980                                Nelarabine                         Sorafenib

  ABT-869_Linifanib                     Capecitabine                              Gefitinib                               Nilotinib                          Sotrastaurin

  ABT-888 (Veliparib)                   Carboplatin                               Gemcitabine HCl                         Nilutamide                         SR1 HCl

  AC220_Quizartinib                     Carfilzomib                               Goserelin acetate                       Nitrogen mustard                   Stattic

  Acrichine                             Carmustine                                GSK 269962                              Nutlin-3                           Streptozocin

  AG-014699_Rucaparib                   Celecoxib                                 GSK 650394                              NVP-AUY922                         Sunitinib

  Allopurinol                           CHIR-258 (Dovitinib)                      GSK1120212\_ Trametinib                 NVP-BEZ235_Dactolisib              TAK-733

  Altretamine                           Chlorambucil                              GSK2126458                              NVP-BGJ398                         TAK-901

  Amifostine                            Chloroquine diphosphate                   GSK2636771                              NVP-LDE225 (Diphosphate salt)      Tamoxifen citrate

  Aminoglutethimide                     CHR 2797_Tosedostat                       HA-1077 (Fasudil)                       Obatoclax Mesylate (GX15-070)      Tandutinib

  Aminolevulinic acid                   CI-994_Tacedinaline                       Homoharringtonine                       Olaparib                           Tasocitinib_Tofacitinib

  Amonafide                             Cisplatin aq                              Hydroxyurea                             OSI-027                            Temozolomide

  Anagrelide                            Cladribine                                I-BET151 (GSK1210151A)                  OSI-906_Linsitinib                 Teniposide

  Anastrozole                           Clafen (Cyclophos-phamide, Endoxan)       Idarubicin HCl                          Oxaliplatin                        Tetramisole HCl

  AP24534 (Ponatinib)                   Clofarabine                               Ifosfamide                              PAC-1                              TGX-221

  ARQ 197_Tivantinib                    Clomifene citrate                         Imatinib                                Paclitaxel                         Thalidomide

  ARRY-162_MEK-162                      CPI-613                                   Imiquimod                               Panobinostat                       Thio-TEPA

  Arsenic(II**I**) oxide                Crenolanib                                INCB018424 (free base, Ruxolitinib)     Pazopanib                          Thioguanine

  AS703026_Pimasertib                   Crizotinib                                Indibulin                               PCI-32765_Ibrutinib                Thiotepa

  Aspirin (Acetylsalicylic Acid)        CUDC-101                                  Iniparib (BSI-201, IND-71677)           PD-0332991                         Tipifarnib (Zarnestra)

  AT 101                                Cyclophosphamide                          INK128                                  Pemetrexed                         Topotecan HCl

  AT-406                                CYT-387_Momelotinib                       Irinotecan                              Pentostatin                        Toremifene citrate

  AT9283                                Cytarabine HCl                            Ixabepilone                             Perifosine aq/PBS                  Tretinoin

  Atorvastatin Ca                       Dabrafenib Mesylate                       JNJ 26854165 (Serdemetan)               PF 431396                          Triethylenemelamine

  Auranofin                             Dacarbazine                               JNJ_26481585_Quisinostat                PF 477736                          Tubacin

  AV-951 (Tivozanib)                    Dacomitinib (monohydrate) (PF-00299804)   KX2-391                                 PF-04691502                        Tubastatin A HCl

  AVN944                                Dactinomycin                              Lapatinib, di-p-toluenesulfonate salt   PF-04708671                        UCN-01

  Axitinib                              Dasatinib                                 Lasofoxifene                            PF-2341066 (Crizotinib)            Uracil mustard

  AZ 3146                               Daunorubicin HCl                          Lenalidomide                            PF-3845                            Valproic acid

  Azacitidine                           DCC-2036_Rebastinib                       Lestaurtinib                            PF4800567 hydrochloride            Valrubicin

  AZD 7762 hydrochloride                Decitabine                                Letrozole                               PF670462                           Vandetanib

  AZD1152-HQPA                          Decitabine (Dacogen)                      Lomeguatrib                             PHA-739358 (Danusertib)            Varespladib

  AZD1480                               Deferoxamine mesylate                     Lomustine, CCNU                         PIK-75 HCl                         Vatalanib

  AZD2014                               Dexamethasone (Decadron)                  LY 333531 mesylate- Ruboxistaurin       Pilocarpine                        Vemurafenib

  AZD4547                               Dexrazoxone                               LY2157299                               Pipobroman                         VER 155008

  AZD6244 (Selumetinib)                 Dinaciclib (SCH727965)                    LY2228820 (CP868569)                    PKC412_Midostaurin                 Vinblastine sulfate

  AZD8055                               Docetaxel                                 LY2603618_Rabusertib                    Plerixafor                         Vincristine Sulfate (Oncovin)

  BAY 73-4506_Regorafenib               Doxorubicin                               LY2784544_Gandotinib                    Plicamycin                         Vinorelbine tartrate

  Belinostat (PXD101)                   Doxorubicin HCl                           Masitinib                               PLX4032_Vemurafenib                Vismodegib

  Bendamustine HCl                      EMD1214063                                MDV3100_Enzaluamide                     Pralatrexate                       Vorinostat

  Bexarotene                            Entinostat                                Megestrol acetate                       Pravastatin                        VX-11e

  BI 2536                               Enzastaurin                               Melphalan                               Prednisolone                       XAV-939

  BI 6727_Volasertib                    Epothilone B (Patupilone)                 Mercaptopurine                          Prednisone                         XL-147

  BIBF 1120_Nintedanib                  Erlotinib HCl                             Metformin\                              Prima-1 Met                        XL184_Cabozantinib
                                                                                  hydrochloride aq                                                           

  BIBW2992 (Tovok)\_Afatinib            Estramustine sodium phosphate             Methotrexate                            Procarbazine                       XL880 (Foretinib)

  Bicalutamide                          Etoposide                                 Methoxsalen                             PX-866_Sonolisib                   YM155

  BIIB021                               Everolimus                                Methylprednisolone                      Quinacrine HCl                     Zolendronic acid

  Bimatoprost                           Exemestane                                MGCD-265                                R406_Tamatinib                     ZSTK474

  BIRB 796 (Doramapimod)                FG-4592                                   MGCD0103_Mocetinostat                   RAF265                             

  BKM-120_Buparlisib                    Finasteride                               Mithramycin A                           Raloxifene HCl                     
  ------------------------------------- ----------------------------------------- --------------------------------------- ---------------------------------- -------------------------------

###### 

IC~50~ (μM) for each drug at 0 and 4 Gy in a panel of colorectal cancer cell lines

  ---------------------------------------------------------------------------------------------------------------------------------------------
  Cell line      5-FU IC~50~        Vorinostat IC~50~    PI-103 IC~50~        Olaparib IC~50~        Rucaparib IC~50~     Mitoxantrone IC~50~
  -------------- ------------------ -------------------- -------------------- ---------------------- -------------------- ---------------------
  LS411 0 Gy     24.67\             6.79\                5.23\                24.46\                 \*62.18              16.75\
                 (17.58 to 35.46)   (3.99 to 11.91)      (3.47 to 8.12)       (15.71 to 38.89)                            (12.32 to 22.98)

  LS411 4 Gy     21.95\             14.55\               2.76\                2.11\                  1.72\                7.8\
                 (12.37 to 40.8)    (9.69 to 22.27)      (1.57 to 4.96)       (1.09 to 4.18)         (0.49 to 8.54)       (5.63 to 10.89)

  VACO5 0 Gy     2.54\              3.45\                1.91\                10.5\                  34.03\               3.49\
                 (1.95 to 3.35)     (2.47 to 4.9)        (1.05 to 3.58)       (3.83 to 29.59)        (21.2 to 58.03)      (0.87 to 14.64)

  VACO5 4 Gy     0.99\              3.37\                0.48\                0.75\                  3.07\                1.24\
                 (0.83 to 1.19)     (2.85 to 4)          (0.34 to 0.71)       (0.43 to 1.3)          (0.61 to 11.91)      (0.56 to 2.99)

  RKO 0 Gy       2.51\              6.51\                1.55\                8.63\                  61.23\               9.75\
                 (1.93 to 3.29)     (3.89 to 11.26)      (0.95 to 2.54)       (4.32 to 17.22)        (30.07 to 167.4)     (6.21 to 15.44)

  RKO 4 Gy       1.15\              2.14\                0.33\                0.35\                  0.3\                 2.9\
                 (0.73 to 1.90)     (1.2 to 4.15)        (0.20 to 0.57)       (0.15 to 0.78)         (0.03 to 1.59)       (1.59 to 5.46)

  HT29 0 Gy      9.12\              3.47\                \* \>20              17.93\                 51.82\               6.58\
                 (6.67 to 12.66)    (2.42 to 5.03)                            (4.14 to 75.29)        (33.61 to 86.34)     (1.24 to 78.99)

  HT29 4 Gy      6.6\               4.18\                \* 12.94             2.21\                  5.48\                3.06\
                 (5.24 to 8.36)     (2.6 to 6.94)                             (1.25 to 3.55)         (2.49 to 11.75)      (0.88 to 12)

  OXCO4 0 Gy     16.71\             6.09\                2.42\                26.88\                 13.11\               0.89\
                 (14.13 to 19.85)   (3.69 to 10.41)      (1.82 to 3.24)       (16.82 to 43.79)       (10.42 to 16.58)     (0.61 to 1.33)

  OXCO4 4 Gy     9.45\              3.82\                1.13\                6.07\                  2.5\                 0.59\
                 (7.92 to 11.32)    (2.69 to 5.49)       (0.87 to 1.47)       (4.73 to 7.82)         (1.74 to 3.61)       (0.44 to 0.78)

  CW2 0 Gy       20.19\             4.49\                4.97\                17.05\                 36.91\               19.81\
                 (15.17 to 27.24)   (2.9 to 7.08)        (3.14 to 8.17)       (6.48 to 44.79)        (30.48 to 45.16)     (11.2 to 35.76)

  CW2 4 Gy       \*20.1             5.33\                4.21\                \* \>20                \* \>30              21.02\
                                    (3.59 to 7.99)       (1.49 to 14.87)                                                  (12.56 to 186)

  DLD1 0 Gy      8.6\               6.26\                1.69\                \* \>100               \*30.41              4.08\
                 (6.77 to 10.99)    (3.07 to 13.72)      (0.94 to 3.08)                                                   (1.49 to 12.46)

  DLD1 4 Gy      7.78\              3.25\                0.52\                1.74\                  0.44\                1.9\
                 (5.26 to 11.81)    (2.02 to 5.42)       (0.29 to 0.95)       (0.89 to 3.5)          (0.15 to 2.1)        (1.33 to 2.72)

  CCK81 0 Gy     29.85\             10.4\                1.27\                \>100                  \*48.51              \*16.51
                 (23.48 to 38)      (5.37 to 21.34)      (0.92 to 1.76)                                                   

  CCK81 4Gy      20.77\             7.84\                1.07\                13.05\                 45.05\               22.6\
                 (16.64 to 26.01)   (4.13 to 15.86)      (0.81 to 1.44)       (7.62 to 22.53)        (11.83 to 105.1)     (11.62 to 60.7)

  C10 0 Gy       43.38\             2.05\                0.98\                \* \>100               23.7\                3.92\
                 (31.27 to 60.93)   (0.82 to 6.16)       (0.45 to 2.19)                              (20.64 to 222.2)     (1.84 to 8.96)

  C10 4 Gy       39.86\             10.21\               0.53\                \* \>100               22.4\                2.18\
                 (17.15 to 101.3)   (1.3 to 74.5)        (0.27 to 1.17)                              (6.87 to 130)        (1.14 to 4.29)

  SW403 0 Gy     1.31\              17.71\               \* \>20              6.18\                  40.51\               2.17\
                 (0.86 to 2.02)     (7.57 to 49.28)                           (1.46 to 26.89)        (27.91 to 61.56)     (0.94 to 5.27)

  SW403 4 Gy     0.73\              7.28\                10.81\               0.85\                  12.39\               1.46\
                 (0.49 to 1.09)     (4.53 to 12.05)      (5.35 to 27.22)      (0.28 to 2.46)         (5.71 to 26.75)      (0.66 to 3.41)

  COLO678 0 Gy   85\                8.68\                2.3\                 \* \>200               \* 48.67             5.96\
                 (37.7 to 197.4)    (1.84 to 64.49)      (1.08 to 5.15)                                                   (2.98 to 12.18)

  COLO678 4 Gy   81.5\              \*5.5                2.24\                \* \>200               \* 45.79             20.31\
                 (70.58 to 129.3)                        (1.09 to 4.85)                                                   (12.29 to 34.44)

  SW1222 0 Gy    10.58\             41.93\               \* \>20              16.72\                 9.78\                2.76\
                 (5.80 to 20.42)    (16.03 to 134)                            (9.97 to 28.91)        (4.56 to 22.31)      (1.63 to 4.8)

  SW1222 4 Gy    3.23\              4.07\                0.75\                0.42\                  \* 0.32              0.73\
                 (2.19 to 4.75)     (2.98 to 5.63)       (0.63 to 0.90)       (0.32 to 0.56)                              (0.32 to 1.83)

  HCA7 0 Gy      27.64\             1.29\                2.95\                3.99\                  48.51\               1.93\
                 (22.63 to 33.87)   (0.93 to 1.80)       (1.71 to 5.26)       (3.16 to 5.05)         (35.36 to 68.98)     (0.57 to 6.89)

  HCA7 4 Gy      19.82\             0.82\                1.14\                0.24\                  0.36\                0.75\
                 (16.49 to 23.89)   (0.70 to 0.97)       (0.79 to 1.66)       (0.18 to 0.32)         (0.19 to 0.66)       (0.24 to 2.53)

  HT55 0 Gy      10.53\             2.11\                2.87\                41.07(4.96 to 28.01)   12.2\                1.26\
                 (7.91 to 14.17)    (1.51 to 3)          (0.95 to 9.99)                              (8.31 to 18.19)      (0.86 to 1.85)

  HT55 4 Gy      12.03\             3.14(1.99 to 5.10)   2.58\                7.88\                  1.47\                1.27\
                 (8.91 to 16.48)                         (1.85 to 3.63)       (0.88 to 3.66)         (0.4 to 5.18)        (0.79 to 2.08)

  C99 0 Gy       3.34\              3.53\                23.77\               14.01\                 39.28\               1.15\
                 (2.11 to 5.72)     (1.8 to 7.46)        (8.94 to 31.98)      (4.11 to 53.54)        (21.29 to 81.87)     (0.58 to 2.31)

  C99 4 Gy       4.44\              3\                   0.97\                0.44\                  14.2\                0.49\
                 (2.37 to 8.86)     (1.66 to 5.92)       (0.30 to 3.48)       (0.22 to 0.87)         (0.16 to 18)         (0.27 to 0.92)

  Cell line      AZD-7762 IC~50~    PF4777 IC~50~        AZD-6244 IC~50~      Trametinib IC~50~      Vemurafenib IC~50~   

  LS411 0 Gy     2.69\              3.84\                11.92\               2.03\                  58.81\               
                 (1.5 to 6.50)      (2.91 to 5.08)       (5.13 to 39.4)       (0.08 to 25.26)        (30.19 to 144.8)     

  LS411 4 Gy     0.41\              1.49\                6.94\                1.81\                  20.39\               
                 (0.25 to 0.69)     (1.06 to 1.83)       (2.62 to 24.83)      (0.006 to 48.6)        (4.63 to 210.7)      

  RKO 0 Gy       0.02\              0.47\                \*148.75             0.09\                  15.14\               
                 (0.015 to 0.03)    (0.31 to 0.71)                            (0.03 to 0.3)          (4.37 to 57.2)       

  RKO 4 Gy       0.005\             0.19\                4.62\                0.03\                  4.57\                
                 (0.004 to 0.008)   (0.15 to 0.25)       (0.74 to 46.47)      (0.01 to 0.07)         (0.99 to 29.93)      

  VACO5 0 Gy     0.05\              1.5\                 14.81\               0.01\                  9.37\                
                 (0.03 to 0.11)     (1.06 to 2.16)       (7.95 to 29.18)      (0.007 to 0.017)       (6.57 to 13.45)      

  VACO5 4 Gy     0.01\              0.28\                7.08\                0.003\                 3.86\                
                 (0.004 to 0.02)    (0.23 to 0.34)       (4.28 to 11.86)      (0.003 to 0.004)       (2.6 to 5.84)        

  HT29 0 Gy      0.03\              4.08\                2.34(1.02 to 5.62)   0.02\                  13.1\                
                 (0.02 to 0.06)     (2.58 to 6.89)                            (0.01 to 0.04)         (5.49 to 32.24)      

  HT29 4 Gy      0.01\              1.57\                1.87(0.62 to 6.39)   0.01\                  11.76\               
                 (0.003 to 0.03)    (1.03 to 2.45)                            (0.007 to 0.02)        (6.68 to 20.96)      

  OXCO4 0 Gy     2.14\              1.54\                3.04\                \*0.15                 14.57\               
                 (1.39 to 3.73)     (1.08 to 2.22)       (1.76 to 5.35)                              (10.14 to 21.19)     

  OXCO4 4 Gy     0.17\              0.76\                0.82\                \*0.06                 10.6\                
                 (0.13 to 0.22)     (0.54 to 1.09)       (0.33 to 2.4)                               (4.09 to 28.44)      

  CW2 0 Gy       2.16\              26.75\               1.72\                0.46\                  \*53.05              
                 (1.17 to 5.32)     (21.9 to 32.78)      (0.47 to 9.39)       (0.2 to 1.24)                               

  CW2 4 Gy       \* \>2             20.75\               \* \>10              0.18\                  \*49.07              
                                    (6.06 to 71.96)                           (0.076 to 0.44)                             

  DLD1 0 Gy      0.14\              \* 15.02             \* \>20              \* \>1                 \*66.41              
                 (0.1 to 0.21)                                                                                            

  DLD1 4 Gy      0.02\              5.46\                \* \>20              0.08\                  33.24\               
                 (0.01 to 0.05)     (2.36 to 12.91)                           (0.02 to 0.59)         (14.01 to 84.84)     

  CCK81 0 Gy     0.75\              \* \>10              \* \>20              \*\>1                  \* \>160             
                 (0.43 to 1.42)                                                                                           

  CCK81 4Gy      0.11\              \* \>10              \* \>20              \* \>1                 \* \>160             
                 (0.08 to 0.17)                                                                                           

  C10 0 Gy       0.12\              \*10.08              \*25.69              0.68\                  53.16\               
                 (0.1 to 0.15)                                                (0.26 to 3.31)         (30.73 to 99.45)     

  C10 4 Gy       0.12\              \* \>10              \* \>20              0.29\                  48.79\               
                 (0.08 to 0.2)                                                (0.13 to 0.74)         (23.05 to 119.8)     

  SW403 0 Gy     0.26\              0.79\                6.45\                \*2.03                 \* \>80              
                 (0.18 to 0.37)     (0.44 to 1.41)       (3.02 to 15.7)                                                   

  SW403 4 Gy     0.13\              0.37\                1.71\                \* 1.68                \* \>80              
                 (0.1 to 0.16)      (0.22 to 0.62)       (1.08 to 2.76)                                                   

  COLO678 0 Gy   \* \>2             \*25.14              1.12\                0.006\                 \* \>80              
                                                         (0.72 to 1.78)       (0.005 to 0.008)                            

  COLO678 4 Gy   \* \>2             \*25.39              1.47\                0.005\                 \* \>80              
                                                         (1.07 to 2.04)       (0.002 to 0.01)                             

  SW1222 0 Gy    0.07\              6.26\                3.75\                0.23\                  \* \>160             
                 (0.05 to 0.1)      (4.02 to 10.64)      (0.64 to 45.5)       (0.09 to 0.69)                              

  SW1222 4 Gy    0.02\              1.19\                0.61\                0.04\                  39.5\                
                 (0.02 to 0.02)     (0.76 to 1.91)       (0.43 to 0.87)       (0.02 to 0.07)         (27.01-57.36)        

  HCA7 0 Gy      0.06\              2.37\                \* \>20              0.41\                  196.8\               
                 (0.01 to 0.47)     (1.76 to 3.26)                            (0.21 to 0.89)         (178.93 to 231)      

  HCA7 4 Gy      0.01\              0.42\                \*18.77              0.15\                  116.7\               
                 (0.00 to 0.14)     (0.36 to 0.49)                            (0.09 to 0.24)         (64.29 to 256.3)     

  HT55 0 Gy      0.06\              0.97\                1.55\                0.08\                  49.39\               
                 (0.05 to 0.09)     (0.73 to 1.28)       (0.28 to 5.02)       (0.03 to 0.29)         (15.7 to 169.4)      

  HT55 4 Gy      0.02\              0.37\                1.55\                0.05\                  50.77\               
                 (0.01 to 0.02)     (0.3 to 0.47)        (0.41 to 3.33)       (0.03 to 0.09)         (22.77 to 132)       

  C99 0 Gy       0.12\              3.75\                1.27\                0.01\                  \* \>160             
                 (0.07 to 0.22)     (1.92 to 8.38)       (0.32 to 5.5)        (0.007 to 0.023)                            

  C99 4 Gy       0.34\              1.43\                0.38\                0.004\                 \* \>160             
                 (0.07 to 2.32)     (0.32 to 7.72)       (0.16 to 1.08)       (0.002 to 0.007)                            
  ---------------------------------------------------------------------------------------------------------------------------------------------

[^1]: \*These authors contributed equally to this work.
